 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Lutathera (lutetium Lu 177 dotatate) / Novartis
Impact of fitting technique and number of SPECT-CT time points in Renal Dosimetry Post 177Lu-DOTATATE Therapy (Hall Y4-Y9) - Sep 27, 2024 - Abstract #EANM2024EANM_686;
P=N/A
Removing the 24-hour time point has only a slight impact on injected activity and absorbed dose estimates to the kidneys. One time point dosimetry provided reasonable results with high correlation (r=0.963) with modest bias (8.9
- Lutathera (lutetium Lu 177 dotatate) / Novartis
First outcomes from OZM-067 - a multicenter single arm study of 177Lu-DOTATATE therapy for primary site agnostic 68Ga-DOTATATE PET positive progressive metastatic neuroendocrine tumors (801B (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1759;
At 12 mths, PFS of 81% and OS of 92% were consistent with those achieved for midgut primaries alone. Individualized dosimetry as part of a multicenter trial was feasible, enabling dose escalation while maintaining the renal dose within a target threshold of 22 Gy and a favorable toxicity profile.
- Lutathera (lutetium Lu 177 dotatate) / Novartis
Quality of life (QoL) benefits following 177 Lu-DOTATATE therapy in patients (pts) with 68 Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5253;
P=N/A
Sexual fc and body image had the largest improvement. Clinical trial information: NCT02743741.
- ||| lutetium-177 Octreotate (PNT2003) / POINT Biopharma, PNT2002 / POINT Biopharma
Licensing / partnership, M&A: $LNTH Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 https://t.co/5ClNLYgJK0 (Twitter) - Nov 14, 2022
- || NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors (clinicaltrials.gov) - Apr 11, 2022
P=N/A, N=195, Active, not recruiting, Sponsor: University Health Network, Toronto
Clinical trial information: NCT02743741. Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jun 2026
- || Lutathera (lutetium Lu 177 dotatate) / Novartis, lutetium-177 Octreotate (PNT2003) / POINT Biopharma
Clinical, Journal: The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. (Pubmed Central) - Feb 19, 2022
In patients with SSTR-RADS 5 PM-NETs treated with 177Lu-DOTATATE, there was similar response to therapy for all lesions with PET-generated Krenning score ≥2. No correlation was found between lesion's POD and level of tracer uptake.
- ||| Enrollment open: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=195, Recruiting, Sponsor: University Health Network, Toronto
No correlation was found between lesion's POD and level of tracer uptake. Not yet recruiting --> Recruiting
- ||| New trial: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=195, Not yet recruiting, Sponsor: University Health Network, Toronto